Aptar Pharma's clinical study confirms a major advance in dry powder inhalers

World leader in nasal and pulmonary drug delivery devices, Aptar Pharma will unveil the results of the latest patient-focused clinical studies using the Prohaler Dry Powder Inhaler, at the upcoming RDD (Respiratory Drug Delivery) scientific conference.

RDD® 2012 will be held in Phoenix, Arizona, from May 15 th-17 th 2012.

Aptar Pharma in tune with the market, patients and prescribers

Before starting development of Prohaler®, Aptar Pharma carried out a series of investigations and acceptance studies with healthcare professionals. The aim of these studies was to determine Dry Powder Inhaler (DPI) user expectations and preferences.

The next step was to extend these investigations to understand the patient/device interface during inhalation and verify that all the necessary conditions were met for the correct dose of medication to be administered.

This took place during a hospital-based clinical study which was carried out at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France. The study was led by Professor Patrice Diot, an eminent respiratory physician and formerly President of ISAM (The International Society for Aerosols in Medicine).

Results showed that all study participants with either asthma or Chronic Obstructive Pulmonary Disease (COPD) could trigger the device and inhale enough air for the medication to reach the lungs, regardless of how ill they were.

Both patients and doctors surveyed confirmed the advantages of Prohaler® in terms of ergonomics and ease of use. These provide this DPI with optimized handling characteristics for consistent and effective dose delivery. It was clearly demonstrated that Prohaler® met expectations, and had the support of both patients and prescribers.

Prohaler®, the smart DPI for optimal patient compliance

The Prohaler® DPI has been developed with a patient-based design approach which makes it intuitive and simple to use by all asthma and COPD patients.

Prohaler® features a novel powder dispersion technology enabling consistent lung deposition even while operating at relatively low patient inhalation flow rates. The results of the research showed that Prohaler® has excellent ergonomics, providing intuitive and constant handling characteristics. It is easy to use, with only 3 simple steps needed: open the device, inhale and close it; inhaling triggers the release of a full dose of medication. And a dose counter reminds the patient how many doses are left in the device.

Prohaler® incorporates visual and audible feed-back systems to facilitate ease-of-use and patient compliance.

Prohaler® also has a unique patient safety feature to avoid any risk of double-dosing and wasted doses. And the drug product is protected inside individual blisters which are only opened upon inhalation by the patient, providing optimal powder protection.

A new step forward in delivering asthma and COPD treatment via the pulmonary route

Asthma and COPD are very common chronic diseases. They represent a global market estimated at US$ 31 billion in drug sales in 2011 growing 3% (Datamonitor).

The majority of respiratory treatments are delivered via the pulmonary route, using either pressurized Metered Dose Inhalers (pMDIs) or more recently DPIs. Because they eliminate the problem of synchronization between actuation and inhalation, DPIs are considered easier to use than pMDIs. In addition, DPIs do not contain propellant and are therefore more environmentally- friendly.

Dr. Gerallt Williams will give a presentation on a Prohaler® patient-focused study during RDD® 2012, the major worldwide scientific event for inhalation science. This presentation, entitled “Powder Inhaler Modifications Resulting From Patient Focused Testing”, will take place on May 17th, at 2.30 pm.

“At Aptar Pharma, we are extremely pleased to unveil the results of this new hospital-based patient-focused study with Prohaler® . This device is designed to meet the needs of patients with regard to safety and comfort as well as to satisfy medical professionals' recommendations, pharmaceutical industry expectations and the requirements of regulatory bodies.” states Dr. Gerallt Williams, Director Scientific Affairs, Aptar Pharma Prescription Division.

For more information on Prohaler®, please visit our table top at RDD 2012 or click here.
Companies in this article
More in Home